These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8285202)

  • 21. Peritoneal dialysis solutions containing glycerol and amino acids.
    Lameire N; Faict D
    Perit Dial Int; 1994; 14 Suppl 3():S145-51. PubMed ID: 7948264
    [No Abstract]   [Full Text] [Related]  

  • 22. Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients--no effect on nutritional status.
    Dombros NV; Prutis K; Tong M; Anderson GH; Harrison J; Sombolos K; Digenis G; Pettit J; Oreopoulos DG
    Perit Dial Int; 1990; 10(1):79-84. PubMed ID: 2085588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and nutritional consequences of amino acid-based vs glucose-based dialysis solutions in infants and children receiving CAPD.
    Hanning RM; Balfe JW; Zlotkin SH
    Am J Clin Nutr; 1987 Jul; 46(1):22-30. PubMed ID: 3300250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis.
    Goodship TH; Lloyd S; McKenzie PW; Earnshaw M; Smeaton I; Bartlett K; Ward MK; Wilkinson R
    Clin Sci (Lond); 1987 Nov; 73(5):471-8. PubMed ID: 3315397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbohydrate and lipid metabolism during continuous ambulatory peritoneal dialysis (CAPD): the effect of a single dialysis cycle.
    Heaton A; Johnston DG; Burrin JM; Orskov H; Ward MK; Alberti KG; Kerr DN
    Clin Sci (Lond); 1983 Nov; 65(5):539-45. PubMed ID: 6352157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous ambulatory peritoneal dialysis in the treatment of end-stage diabetic nephropathy.
    Grefberg N; Danielson BG; Nilsson P
    Acta Med Scand; 1984; 215(5):427-34. PubMed ID: 6377827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. End-state renal failure in diabetic nephropathy: pathophysiology and treatment.
    Schmitz O; Hansen HE; Orskov H; Mogensen CE; Posborg Petersen V
    Blood Purif; 1985; 3(1-3):120-39. PubMed ID: 3913447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intraperitoneal infusion of dextrose and amino acids on the appetite of rabbits.
    Balaskas EV; Rodela H; Oreopoulos DG
    Perit Dial Int; 1993; 13 Suppl 2():S490-8. PubMed ID: 8399648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids.
    Selby NM; Fialova J; Burton JO; McIntyre CW
    Nephrol Dial Transplant; 2007 Mar; 22(3):870-9. PubMed ID: 17121785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
    Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
    Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of glycerol as an osmotic agent for continuous ambulatory peritoneal dialysis in end-stage renal failure.
    Heaton A; Ward MK; Johnston DG; Alberti KG; Kerr DN
    Clin Sci (Lond); 1986 Jan; 70(1):23-9. PubMed ID: 3510801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAPD in diabetics: use of aminoacids.
    Renzo S; Beatrice D; Giuseppe I
    Adv Perit Dial; 1990; 6():53-5. PubMed ID: 1982840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle.
    Asola M; Virtanen K; Någren K; Helin S; Taittonen M; Kastarinen H; Anderstam B; Knuuti J; Metsärinne K; Nuutila P
    Kidney Int Suppl; 2008 Apr; (108):S131-6. PubMed ID: 18379536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of amino acid dialysate on appetite in CAPD patients.
    Musk M; Anderson H; Oreopoulos D; Leiter L; Bargman J; Pettit J; Jones M
    Adv Perit Dial; 1992; 8():153-6. PubMed ID: 1361775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of peritonitis on insulin and glucose absorption during peritoneal dialysis in diabetic rats.
    Mactier RA; Moore H; Khanna R; Shah J
    Nephron; 1990; 54(3):240-4. PubMed ID: 2179758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of blood glucose in diabetic dialysis patients].
    Hori K; Fujimi S
    Nihon Rinsho; 1992 Jan; 50 Suppl():192-6. PubMed ID: 1578677
    [No Abstract]   [Full Text] [Related]  

  • 38. An animal model for the study of amino acid metabolism in uremia and during peritoneal dialysis.
    Oreopoulos AK; Balaskas EV; Rodela H; Anderson GH; Oreopoulos DG
    Perit Dial Int; 1993; 13 Suppl 2():S499-507. PubMed ID: 8399649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Continuous ambulatory peritoneal dialysis treatment and blood glucose control in diabetics with end-stage diabetic nephropathy].
    Li GW; Liu J; Chen L
    Zhonghua Nei Ke Za Zhi; 1989 Jun; 28(6):360-3, 382. PubMed ID: 2684575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients.
    Taylor GS; Patel V; Spencer S; Fluck RJ; McIntyre CW
    Clin Nephrol; 2002 Dec; 58(6):445-50. PubMed ID: 12508967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.